Global Sterile Manufacturing And Lyophilization Capabilities Of Large And Small Molecule Biologics

Sterilize sterilizing GettyImages-1340554274

The recent boom of biologics has impacted the traditional approach for sterile fill-finish services as the stability challenges of many biologics require lyophilization to improve product stability. This evolution is increasing the demand for lyophilization manufacturing technology in support of parenteral products as well as experienced CDMOs with scalable development and manufacturing solutions that can meet the demands of the ever-growing biologics market and bring life-changing therapies to patients faster.

Whether it be for complex formulation process development, scale up, technology transfer or bespoke packaging of biologic drug products, a tailored-service approach allows CDMOs to deliver flexible, agile and timely solutions to help bring life-changing therapies to patients. PCI’s global manufacturing capabilities are in complex formulations, high potency, and lyophilization and our capabilities cover a broad range of injectables including nanoparticles, mRNA, mAbs, proteins, oligonucleotides, and other biologics across multiple delivery formats. Explore the advantages of partnering with an experienced, robust CDMO capable of reducing costs and bringing your product to market faster.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma